Nonsegmental vitiligo
Conditions
Brief summary
Percentage change from baseline to Week 24 in F-VASI score.
Detailed description
Achievement of ≥75% improvement from baseline in the F-VASI (F-VASI75) at Week 24., Percentage change from baseline to Week 24 in T-VASI score., Achievement of ≥50% improvement from baseline in T-VASI (T-VASI50) at Week 24., Achievement of F-VASI50, F-VASI75, and F- VASI90 at Week 12, Week 24, Week 36, and Week 48., Achievement of T-VASI50, T-VASI75, and T- VASI90 at Weeks 12, Week 24, Week 36, and Week 48., Achievement of VNS of 4 or 5, at Week 12, Week 24, Week 36, and at Week 48., Occurrence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
Interventions
DRUGGIA632
DRUGPlacebo to GIA632
Sponsors
Novartis Pharma AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage change from baseline to Week 24 in F-VASI score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Achievement of ≥75% improvement from baseline in the F-VASI (F-VASI75) at Week 24., Percentage change from baseline to Week 24 in T-VASI score., Achievement of ≥50% improvement from baseline in T-VASI (T-VASI50) at Week 24., Achievement of F-VASI50, F-VASI75, and F- VASI90 at Week 12, Week 24, Week 36, and Week 48., Achievement of T-VASI50, T-VASI75, and T- VASI90 at Weeks 12, Week 24, Week 36, and Week 48., Achievement of VNS of 4 or 5, at Week 12, Week 24, Week 36, and at Week 48., Occurrence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). | — |
Outcome results
None listed